⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of FORE Biotherapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
FORE Biotherapeutics
↗Philadelphia, USA
FORE Biotherapeutics (Fore Bio) is a clinical-stage precision oncology company dedicated to developing innovative treatments for patients with the hardest-to-treat cancers. The company leverages a proprietary functional genomics platform to identify and develop targeted therapies for unaddressed tumor mutations, focusing on compounds with known clinical profiles to create a clear development path.
Its lead asset, plixorafenib (FORE8394), is a novel, orally available, next-generation BRAF inhibitor designed to target a broad range of BRAF alterations (V600 and non-V600, including class 2 mutants and fusions) while minimizing paradoxical MAPK pathway activation. The company is currently advancing plixorafenib through the registration-intended global FORTE phase 2 clinical trial.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
FUNDING
Stage:Series D
Investors:SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, 3B Future Health Fund
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (Registrational)
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Argot Partners (Investor/Media Relations)
COMPETITION
Position:Emerging
Competitors:Novartis, Roche, AstraZeneca, Merck, Pfizer, Blueprint Medicines, Revolution Medicines
LEADERSHIP
Key Executives:
William R. Hinshaw - CEO
Board Members:Dieter Weinand (Chairman)
LINKS
Website:forebio.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with FORE Biotherapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.